Key result
Muscone attenuates cardiac hypertrophy, fibrosis, and inflammation in mice via STAT3, MAPK, and TGF-β/SMAD inhibition.
Why the study?
Although studies have confirmed the cardioprotective effects of muscone, its effects on cardiac hypertrophy and underlying mechanisms remain unclear.
Should not change practice; leaves open translation of muscone to human cardiac remodeling.
Context: Muscone is a chemical monomer derived from musk. Although many studies have confirmed the cardioprotective effects of muscone, the effects of muscone on cardiac hypertrophy and its potential mechanisms are unclear. Objective: The aim of the present study was to investigate the effect of muscone on angiotensin (Ang) II-induced cardiachypertrophy. Materials and methods: The viability of H9C2 and AC16 cells was assessed by CCK8 assay. The expression of proteins was evaluated by RT-PCR and Western blot analysis. Echocardiographic paraments were obtained by a Visual sonics high resolution Vevo 2100 system. H&E staining was used to assess myocardial structural changes. Masson trichrome staining was used to assess degree of fibrosis. Serum Biochemical Indexes were detected by automatic chemistry analyzer. Results: In the present study, we found for the first time that muscone exerted inhibitory effects on Ang II-induced cardiac hypertrophy and cardiac injury in mice. Secondly, we showed that muscone attenuated cardiac injury by reducing the secretion of proinflammatory cytokines and promoting the secretion of anti-inflammatory cytokines. Moreover, we found that muscone exerted cardioprotective effects by inhibiting phosphorylation of key proteins in the STAT3, MAPK and TGF-β/SMAD pathways. In addition, the in vivo and in vitro validation found no significant toxicity or side effects of muscone on normal cells and organs. Discussion and conclusions: Muscone could attenuate Ang II-induced cardiac hypertrophy, in part, by inhibiting the STAT3, MAPK, and TGF-β/SMAD signaling pathways.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) studied Angiotensin II-induced cardiac hypertrophy (n=36). Muscone vs. Angiotensin II alone and Valsartan 4 mg/kg/d was evaluated on Echocardiographic parameters (LVEF, LVFS, LVID, LVM) and anatomical parameters (HW/BW ratio) (p=<0.05). Muscone significantly attenuated Angiotensin II-induced cardiac hypertrophy, fibrosis, and inflammation in mice by inhibiting the STAT3, MAPK, and TGF-β/SMAD signaling pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: